Copyright © 2015 Shogo Hosogoe et al.This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. A 47-year-old Japanese man was diagnosed with prostate cancer in February 1995 (Initial PSA 77.2 ng/mL, GS3 + 4, cT3N0M0). He underwent radical prostatectomy after androgen deprivation therapy (ADT) in June 1995. Nine years after operation, he was diagnosed with local recurrence of prostate cancer and he received postoperative external beam radiation therapy (EBRT) (70Gy). By May 2008, the PSA dropped to 0.33 ng/mL, and a CT scan showed that the mass had disappeared. On April 2012, the PSA onc...
Background: Radical external beam radiotherapy (EBRT) is a standard treatment for prostate cancer pa...
Recurrence of prostate cancer after initial treatment with radiation therapy (RT) is highly dependen...
Purpose: Recent work has demonstrated the return of hormone sensitivity after palliative chemotherap...
A 47-year-old Japanese man was diagnosed with prostate cancer in February 1995 (Initial PSA 77.2 ng/...
The article describes a successful experience of using high-dose rate brachytherapy (192Ir) in patie...
OBJECTIVES: The treatment of recurrent prostate cancer after radiotherapy or brachytherapy through r...
International audienceSalvage brachytherapy after a first prostate radiation therapy is an emerging ...
Purpose: Locally recurrent prostate cancer after previous radiation therapy remains challenging. One...
Prostate cancer is the most common male malignancy. Radiation therapy and radical prostatectomy are ...
Background. Prostate cancer (PCa) is one of the most common malignant diseases in men worldwide, wit...
No standard treatment exists for locally relapsed prostate cancer after primary external beam radiot...
A 67-year-old man presented with a slow increase of prostate-specific antigen value after radical pr...
AIM OF THE STUDY: To evaluate the long-term follow-up in patients undergoing external beam radiothe...
PurposeRetrospective, single-institution analysis of clinical outcomes and treatment-related toxicit...
Background/aim: Low dose rate brachytherapy has been used as salvage therapy for locally recurrent p...
Background: Radical external beam radiotherapy (EBRT) is a standard treatment for prostate cancer pa...
Recurrence of prostate cancer after initial treatment with radiation therapy (RT) is highly dependen...
Purpose: Recent work has demonstrated the return of hormone sensitivity after palliative chemotherap...
A 47-year-old Japanese man was diagnosed with prostate cancer in February 1995 (Initial PSA 77.2 ng/...
The article describes a successful experience of using high-dose rate brachytherapy (192Ir) in patie...
OBJECTIVES: The treatment of recurrent prostate cancer after radiotherapy or brachytherapy through r...
International audienceSalvage brachytherapy after a first prostate radiation therapy is an emerging ...
Purpose: Locally recurrent prostate cancer after previous radiation therapy remains challenging. One...
Prostate cancer is the most common male malignancy. Radiation therapy and radical prostatectomy are ...
Background. Prostate cancer (PCa) is one of the most common malignant diseases in men worldwide, wit...
No standard treatment exists for locally relapsed prostate cancer after primary external beam radiot...
A 67-year-old man presented with a slow increase of prostate-specific antigen value after radical pr...
AIM OF THE STUDY: To evaluate the long-term follow-up in patients undergoing external beam radiothe...
PurposeRetrospective, single-institution analysis of clinical outcomes and treatment-related toxicit...
Background/aim: Low dose rate brachytherapy has been used as salvage therapy for locally recurrent p...
Background: Radical external beam radiotherapy (EBRT) is a standard treatment for prostate cancer pa...
Recurrence of prostate cancer after initial treatment with radiation therapy (RT) is highly dependen...
Purpose: Recent work has demonstrated the return of hormone sensitivity after palliative chemotherap...